Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2012 | 01:16am CET

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
12/10 NOVARTIS : Primary analysis results from Novartis pivotal JULIET trial show Kymr..
12/10 NOVARTIS : Primary analysis results from Novartis pivotal JULIET trial show Kymr..
12/09 NOVARTIS : $32,000 Federal Contract Awarded to Alcon Laboratories
12/08DJROCHE : Novartis's Italian Heads Risk Trial for Alleged Market Rigging -Reuters
12/08 ADVANCED ACCELERATOR APPLICATION : s Announces Commencement of Novartis Tender O..
12/08 ROCHE, NOVARTIS' ITALIAN HEADS RISK : sources
12/08 NOVARTIS : Sandoz announces new Phase I data showing proposed biosimilar pegfilg..
12/07 NOVARTIS : Patent Issued for Systems and Techniques for Tissue Manipulation duri..
12/07 NOVARTIS : Patent Issued for Methods and Systems for Pulsed Illumination (USPTO ..
12/07 NOVARTIS : Patent Issued for Surgical Microscope with Integrated Optical Coheren..
More news
News from SeekingAlpha
12/10 GILEAD DOUBLES DOWN ON CAR-T : Updates To Thesis
12/08 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 8, 2017
12/08 Novartis' pegfilgrastim biosimilar candidate on par with Neulasta in early-st..
12/08 YOUR DAILY PHARMA SCOOP : Geron Update, Acorda Resubmits NDA, Sage Rallies
12/07 Novartis launches study evaluating higher dose of Cosentyx in patients with a..
Financials ($)
Sales 2017 49 174 M
EBIT 2017 11 962 M
Net income 2017 7 465 M
Debt 2017 17 812 M
Yield 2017 3,39%
P/E ratio 2017 24,31
P/E ratio 2018 21,18
EV / Sales 2017 4,81x
EV / Sales 2018 4,61x
Capitalization 219 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 4,4%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS11.34%218 728
JOHNSON & JOHNSON21.23%377 698
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
MERCK AND COMPANY-7.68%151 559
AMGEN22.20%127 332